Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study

Lauer, 2001, Hepatitis C virus infection [see comment], N Engl J Med, 345, 41, 10.1056/NEJM200107053450107 Fattovich, 2004, Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, 127, S35, 10.1053/j.gastro.2004.09.014 Parkin, 2006, The global health burden of infection-associated cancers in the year 2002, Int J Cancer, 118, 3030, 10.1002/ijc.21731 Lu, 2006, Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan, Int J Cancer, 119, 1946, 10.1002/ijc.22045 Yeh, 2004, Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis, J Hepatol, 41, 659, 10.1016/j.jhep.2004.06.031 Liu, 2009, Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses, Gastroenterology, 136, 496, 10.1053/j.gastro.2008.10.049 Lin, 1993, Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study, J Clin Ultrasound, 21, 303, 10.1002/jcu.1870210502 Yu, 1997, Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers, Am J Epidemiol, 145, 1039, 10.1093/oxfordjournals.aje.a009060 Iloeje, 2006, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053/j.gastro.2005.11.016 Sun, 1999, Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey, J Med Virol, 59, 290, 10.1002/(SICI)1096-9071(199911)59:3<290::AID-JMV5>3.0.CO;2-R Sun, 2001, Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors, J Med Virol, 65, 30, 10.1002/jmv.1097 Lee, 2011, Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2, Gut, 60, 688, 10.1136/gut.2010.220889 Lee, 2010, Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study, J Clin Oncol, 28, 4587, 10.1200/JCO.2010.29.1500 Huang, 2011, Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C, J Clin Oncol, 29, 3643, 10.1200/JCO.2011.36.2335 Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012, in press. Lee, 2011, Response to letter by Lin et al regarding article, “Hepatitis C virus infection and increased risk of cerebrovascular disease”, Stroke, 42, e390, 10.1161/STROKEAHA.110.612291 Lee, 2010, Hepatitis C virus infection and increased risk of cerebrovascular disease, Stroke, 41, 2894, 10.1161/STROKEAHA.110.598136 Hisada, 2005, Hepatitis C virus load and survival among injection drug users in the United States, Hepatology, 42, 1446, 10.1002/hep.20938 Wiese, 2000, Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study, Hepatology, 32, 91, 10.1053/jhep.2000.8169 Wiese, 2005, Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany–a 25-year multicenter study, J Hepatol, 43, 590, 10.1016/j.jhep.2005.04.007 Velosa, 2011, Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis, Dig Dis Sci, 56, 1853, 10.1007/s10620-011-1621-2 Yoshida, 1999, Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy, Ann Intern Med, 131, 174, 10.7326/0003-4819-131-3-199908030-00003 Brown, 2000, Interferon therapy reduces the risk for hepatocellular carcinoma, Gut, 47, 610, 10.1136/gut.47.5.610 Nishiguchi, 1995, Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis, Lancet, 346, 1051, 10.1016/S0140-6736(95)91739-X Yu, 2006, A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan, Antivir Ther, 11, 985, 10.1177/135965350601100811 Shiratori, 2005, Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival, Ann Intern Med, 142, 105, 10.7326/0003-4819-142-2-200501180-00009 Lok, 2012, Preliminary study of two antiviral agents for hepatitis C genotype 1, N Engl J Med, 366, 216, 10.1056/NEJMoa1104430 Zeuzem, 2011, Telaprevir for retreatment of HCV infection, N Engl J Med, 364, 2417, 10.1056/NEJMoa1013086 Suppiah, 2009, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy, Nat Gen, 41, 1100, 10.1038/ng.447 Tanaka, 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C., Nat Genet, 41, 1105, 10.1038/ng.449 Ge, 2009, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, 461, 399, 10.1038/nature08309 Thomas, 2009, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus, Nature, 461, 798, 10.1038/nature08463 Hsu, 2011, Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy, Proc Natl Acad Sci USA, 108, 3719, 10.1073/pnas.1100349108 Eurich, 2012, Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy, Transplantation, 93, 644, 10.1097/TP.0b013e318244f774 Huang, 2012, Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin, J Hepatol, 56, 34, 10.1016/j.jhep.2011.03.029 Lin, 2011, IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection, PLoS One, 6, e18322, 10.1371/journal.pone.0018322 Yu, 2011, Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients, Hepatology, 53, 7, 10.1002/hep.23976 Liu, 2011, Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives, J Gastroenterol Hepatol, 26, 1348, 10.1111/j.1440-1746.2011.06842.x Kumar, 2011, Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma, Nat Genet, 43, 455, 10.1038/ng.809 Miki, 2011, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers, Nat Genet, 43, 797, 10.1038/ng.876 Abu Dayyeh, 2011, A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma, Gastroenterology, 141, 141, 10.1053/j.gastro.2011.03.045 Yu, 2006, A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy, Hepatology, 44, 1086, 10.1002/hep.21363 Lok, 2009, Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease, Gastroenterology, 136, 138, 10.1053/j.gastro.2008.09.014 Lee, 2012, Clinical scoring system for prediction of long-term risk for hepatocellular carcinoma among hepatitis C virus infected patients, Hepatology International, 11 Ghany, 2010, Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C, Gastroenterology, 138, 136, 10.1053/j.gastro.2009.09.007 Fontana, 2008, Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C, Hepatology, 47, 789, 10.1002/hep.22099 Ghany, 2011, Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial, Hepatology, 54, 1527, 10.1002/hep.24550 Yu, 2009, Treatment of chronic hepatitis C in Asia: when East meets West, J Gastroenterol Hepatol, 24, 336, 10.1111/j.1440-1746.2009.05789.x Liu, 2008, Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial, Clin Infect Dis, 47, 1260, 10.1086/592579 Imazeki, 2003, Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study, Hepatology, 38, 493, 10.1053/jhep.2003.50329